Biology subjects

Chandramouli, G. V.

Publications and source records attributed to Chandramouli, G. V..

3 recordsLinked to original sources

bioRxiv2023

Evaluation of a deuterated triarylmethyl spin probe for in vivo R2*-based EPR oximetric imaging with enhanced dynamic range

PurposeIn this study, we compared two triarylmethyl (TAM) spin probes, Ox071 and Ox063 for their efficacy in measuring tissue oxygen concentration by R2*-based oximetry in hypoxic and normoxic conditions. MethodsThe R2* dependence with spin probe and oxygen was calibrated using standard phantom solutions at 1, 2, 5, 10 mM spin probe and 0, 2, 5, 10, 21% oxygen concentrations. For a hypoxic model, in vivo imaging of a MIA PaCa-2 tumor implanted in the hind leg of a mouse was performed on successive days by using either Ox071 or Ox063. For normoxic model, renal imaging of healthy athymic mice was performed under similar conditions. The 3D spin density images acquired under three different gradients and reconstructed by single point imaging modality were used for computing the R2 * values. ResultsThe signal intensities of Ox071 were about three times greater in the phantom solutions than Ox063 in the entire pO2 range investigated. Although histograms computed from the pO2 images of the tumor were skewed towards low pO2 levels for both spin probes due to R2* signal loss, more frequency counts in the normoxic region at pO2 > 32 mmHg could be detected with Ox071. In the normoxic model in kidney, the high pO2 cortex and the low pO2 medulla regions were well delineated. The histograms of high-resolution kidney oximetry images using Ox071 were nearly symmetrical and frequency counts were seen up to 55 mmHg which were missed in Ox063 imaging. ConclusionThis study illustrates Ox071 as a better oximetric probe than Ox063 in terms of sensitivity and the pO2 dynamic range.

biophysics↗

bioRxiv2022

Evofosfamide and Gemcitabine Act Synergistically in Pancreatic Cancer Xenografts by Dual Action on Tumor Vasculature and Inhibition of Homologous Recombination DNA Repair

AimsPancreatic ductal adenocarcinomas (PDACs) form hypovascular and hypoxic tumors which are difficult to treat with current chemotherapy regimens. Gemcitabine (GEM) is often used as a first line treatment for PDACs, but has issues with chemoresistance and penetration in the interior of the tumor. Evofosfamide, a hypoxia activated prodrug, has been shown to be effective in combination with GEM, although the mechanism of each drug on the other has not been established. We used two mouse xenografts from two cell lines (MIA Paca-2 and SU 86.86) with different tumor microenvironmental characteristics to probe the action of each drug on the other. ResultsGEM treatment enhanced survival times in mice with SU.86.86 xenografts (HR =0.35, 95% CI=0.13 to 0.90 p=0.03) but had no effect on MIA Paca-2 mice (HR =0.91, 95% CI=0.37 to 2.25, p=0.84). Conversely, evofosfamide had no effect on SU86.86 mice and did not improve survival times to a statistically significant degree (HR=0.57, 95% CI=0.23 to 1.42, p=0.22). In MIA Paca-2 tumors, which were initially poorly perfused, electron paramagnetic resonance (EPR) imaging showed that oxygenation worsened when treated with GEM, providing a direct mechanism for the activation of evofosfamide by GEM and the effectiveness of evofosfamide and GEM combinations. Sublethal amounts of either treatment enhanced the toxicity of other treatment in vitro in Su86.86 but not in MIAPaca-2. Repair of double stranded DNA lesions was enhanced in the combination treatment in Su86.86 but not MIA Paca-2. InnovationsA possible mechanism for the synergy between evofosfamide and GEM has been proposed. ConclusionThe synergy between GEM and evofosfamide appears to stem from the dual action of GEMs effect on tumor vasculature and the GEM inhibition of the homologous recombination DNA repair process. The relative importance of each pathway is dependent on the tumor microenvironment and merits further study.

cancer biology↗

bioRxiv2022

PEGPH20, a PEGylated Human Hyaluronidase, Induces Radiosensitization by Reoxygenation In Pancreatic Cancer Xenografts. A Molecular Imaging Study

PEGylated human hyaluronidase (PEGPH20) enzymatically depletes hyaluronan, an important component of the extracellular matrix, in tumors. The resultant improvement in vascular patency and perfusion has been shown to increase the delivery of therapeutic molecules. We show that PEGPH20 also improves the efficacy of radiation therapy in a human pancreatic adenocarcinoma BxPC3 mouse model overexpressing hyaluronan synthase 3 (BxPC3-HAS3) while exerting little effect on the corresponding wild type tumors. Mice overexpressing HAS3 developed fast growing, radiation resistant tumors that became rapidly more hypoxic as time progressed. Treatment with PEGPH20 increased survival times when used in combination with radiation therapy, significantly more than either radiation therapy or PEGPH20 alone. Radiosensitization in BxPC3-HAS3 tumors was attributed to an increase in local pO2 as studied by by EPR imaging. No effect on survival, radiation treatment, or pO2 was seen in wild type tumors after PEGPH20 treatment. Dynamic contrast enhanced (DCE) MRI and MRI based blood volume imaging showed improved perfusion/permeability and local blood volume, respectively, in BxPC3-HAS3 tumors after PEGPH20 treatment, accounting for the increase in tumor oxygenation. Photoacoustic imaging indicated immediate changes in tumor oxygenation after treatment. Metabolic MRI using hyperpolarized [1-13C] pyruvate suggested a metabolic shift towards decreased glycolytic flux after PEGPH20 treatment. In summary, the results showed that PEGPH20 may be useful for radiosensitization of pancreatic cancer but only in the subset of tumors with substantial hyaluronan accumulation and the response of the treatment may potentially be monitored non-invasive imaging of the hemodynamic and metabolic changes in the tumor microenvironment.

cancer biology↗